- Home
- FLC vs LFCR Comparison
FLC vs LFCR Comparison
Compare FLC & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SELL
BUY
Current Price
$6.45
Company Overview
Basic Information| Metric | FLC | LFCR |
|---|---|---|
| Founded | N/A | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.4M | 190.9M |
| IPO Year | 2003 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FLC | LFCR |
|---|---|---|
| Price | $15.56 | $6.45 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.28 |
| AVG Volume (30 Days) | 44.4K | ★ 603.2K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $557,559,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.36 |
| 52 Week Low | $15.33 | $3.63 |
| 52 Week High | $18.09 | $8.98 |
Technical Indicators
Market Signals| Indicator | FLC | LFCR |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 75.16 |
| Support Level | N/A | $4.17 |
| Resistance Level | $17.00 | $6.65 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 50.79 | 91.87 |
Price Performance
Historical Comparison FLC
LFCR
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.